Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nimenrix-ModernaTX, Inc.-respiratory syncytial virus infection-human metapneumovirus infection
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
This identifier refers to a Phase 1 clinical trial (NCT06095271) sponsored by ModernaTX, Inc., evaluating two investigational mRNA vaccines: mRNA-1345 and mRNA-1365. mRNA-1345 is a monovalent vaccine designed to protect against respiratory syncytial virus (RSV) by encoding the viral fusion (F) protein in its prefusion conformation. mRNA-1365 is a first-in-class bivalent combination vaccine targeting both RSV and human metapneumovirus (hMPV), also utilizing mRNA to encode viral fusion proteins. Both candidates are encapsulated in lipid nanoparticles (LNPs) for delivery. The trial is an age de-escalation study in healthy infants and utilizes Nimenrix, a marketed quadrivalent meningococcal conjugate vaccine targeting serogroups A, C, W-135, and Y, as an active control in certain cohorts.
- Brand names
- Nimenrix
- Other names
- Nimenrix-ModernaTX, Inc.-respiratory syncytial virus infection-human metapneumovirus infection
02
Targets
RSV F (Respiratory syncytial virus fusion protein)HMPV F (Human metapneumovirus fusion protein)
Beyond the preview
Go deeper on Nimenrix-ModernaTX, Inc.-respiratory syncytial virus infection-human metapneumovirus infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimenrix-ModernaTX, Inc.-respiratory syncytial virus infection-human metapneumovirus infection.